secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001730463-25-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus reports Q1 AUCATZYL revenue $9.0M; UK MHRA approval for r/r B-ALL
-------------------------------------------------------------------------

- Q1 2025 AUCATZYL net product revenue $9.0M, first quarter of launch.
- UK MHRA granted conditional marketing authorization for AUCATZYL in r/r B-ALL.
- Net loss $70.2M ($0.26 per share) vs $52.7M ($0.24) in Q1 2024.
- Cash & marketable securities $516.6M; company well-capitalized for launch and trials.
- Phase 1 CARLYSLE data: 3/6 SLE patients complete renal response; Phase 2 LN trial by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/0001730463-25-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/autl-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001730463-25-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer